Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01642030 · ClinicalTrials.gov registry record · Phase 1

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

A Phase 1 study, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 1
Development phase
132
Enrollment target

NCT01642030: Completed Phase 1 study, sponsored by Johns Hopkins University.

NCT01642030 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 132 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01642030, a Phase 1 study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 1
Development phase
132 participants
Enrollment target

Study Summary

Pain is very common in persons with a history of addiction, but few studies have examined the best treatment of pain in this population. This is a study to determine the pain relief provided by intravenous hydromorphone (Dilaudid) or buprenorphine given to persons maintained on stable doses of methadone or buprenorphine. Experimental sessions will require overnight stays on a residential research unit. In these sessions, persons will be exposed to standard experimental pain techniques at baseline and then rate the relief (if any) provided by the study medication when exposed to the same techniques. Persons will be asked to participate in 2 or 3 sessions, each separated by at least 7 days.

Primary Outcome

The participant places a hand up to the wrist in a circulating water bath maintained at approximately 4 degrees Celsius (up to 5 minutes). The time at which pain develops is the threshold. The time a volunteer's hand remains underwater before pain is unbearable is tolerance.

Interventions

  • DRUG Placebo
  • DRUG Hydromorphone
  • DRUG Buprenorphine

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2013-08
Est. Completion 2017-07
Phase Phase 1
Johns Hopkins University

1,448 total trials

What the finished NCT01642030 record still lists

NCT01642030 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (120% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01642030 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01642030 about?

NCT01642030 is a clinical study titled "Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance". Pain is very common in persons with a history of addiction, but few studies have examined the best treatment of pain in this population. This is a study to determine the pain relief provided by intravenous hydromorphone (Dilaudid) or buprenorphine given to persons maintained on stable doses of metha...

What is the current status of trial NCT01642030?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2013-08. Estimated completion is 2017-07.

What interventions are being tested in trial NCT01642030?

The interventions under investigation include: Placebo (DRUG), Hydromorphone (DRUG), Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT01642030?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01642030's enrollment target sits among peer trials

132 432nd of 2000 higher than 1,562 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01642030, the US trial registry maintained by the National Library of Medicine. NCT01642030 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.